Rehmann Capital Advisory Group Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Rehmann Capital Advisory Group lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.7% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 538 shares of the biopharmaceutical company’s stock after selling 93 shares during the quarter. Rehmann Capital Advisory Group’s holdings in Regeneron Pharmaceuticals were worth $572,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sachetta LLC raised its position in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the last quarter. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter worth approximately $26,000. Finally, Family Firm Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $33,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on REGN shares. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. Evercore ISI lowered their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, Citigroup initiated coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price target for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,099.90.

Regeneron Pharmaceuticals Trading Down 4.1 %

REGN opened at $740.97 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The stock has a fifty day moving average price of $860.87 and a 200-day moving average price of $1,007.41. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a market cap of $81.43 billion, a price-to-earnings ratio of 18.34, a PEG ratio of 2.32 and a beta of 0.08.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.